Allucent is attending the World Orphan Drug Congress in Amsterdam
Meet Allucent’s dedicated team of experts in rare disease and orphan drug experts at the World Orphan Drug Congress, who share your passion for bringing innovative medicines and life-saving therapies to patients around the world. Our extensive clinical and consulting experience, combined with a patient-centric approach, can light the way for the most complex rare disease clinical trials and orphan drug development.
Schedule a meeting to discuss current trends in rare diseases with the A-Team.
SESSION TITLE & DESCRIPTION:
Endpoint Adjudication in Rare Disease Trials: Navigating Uncertainty and Advancing Objectivity in Outcome Assessment
- Sources of uncertainty in rare disease endpoints and strategies to address them.
- Standardizing endpoint definitions and assessment criteria.
- Use of blinded independent adjudication committees.
- Practical steps for implementing effective adjudication processes.
TIME/DATE: October 29th – 11.15 -11.45am
SPEAKERS:
Maria-Cruz Morillo, M.S. Pharmacy
Global Therapeutic Operations Lead, Rare Disease
Milan Marinkov, MD
Executive Medical Director, Rare Diseases Medical Lead
Fill out the form to schedule a meeting.
Share This
